🔴 Capricor Therapeutics is trading 10.65% down today ahead of FDA’s August 22 decision

Capricor Therapeutics is trading 10.65% down at $7.13 as investors reassess Deramiocel’s approval prospects ahead of the FDA’s August 22 decision.

• The decline follows a sharp multi-session rebound, with investors appearing to take profits; an advisory committee voted 9-3 against Deramiocel’s effectiveness.
• Biotech stocks are down 2.47% amid broader market weakness.
• Recent earnings showed no revenue, a $40.7 million quarterly loss, and approximately 12 months of cash runway.